Mounjaro Side Effects: From Nausea To Kidney Problems, Here Are All The Possible Harmful Effects
Quick Read
Summary is AI generated, newsroom reviewed.
Mounjaro (tirzepatide) is a weekly injectable drug for type-2 diabetes that aids weight loss by regulating appetite. Common side effects include nausea, diarrhea, and abdominal pain. Consult a doctor before use and monitor for potential interactions and side e
Mounjaro is a brand name for tirzepatide, a prescription drug primarily used to manage type-2 diabetes. This once-weekly injectable drug helps maintain healthy blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) that regulate insulin secretion and appetite. Recently, it has gained attention in the realm of weight management.
Mounjaro aids in weight loss by promoting feelings of fullness and reducing hunger, which contributes to a lower calorie intake. It is used widely by individuals who are overweight or obese, even those without diabetes, to shed weight more easily.
While there are benefits to using Mounjaro, it can also cause side effects. Below are some of the most common side effects reported:
Side effects of Mounjaro
As with any medication, Mounjaro can cause side effects. Some of the most common side effects reported include:
1. Nausea
This is the most frequently reported side effect and often decreases over time. Mounjaro slows down the emptying of the stomach which can cause nausea.
2. Diarrhea
Some individuals may experience gastrointestinal issues such as diarrhea, which can subside as the body adjusts.
3. Vomiting
Similar to nausea, vomiting can occur, especially when starting the medication.
4. Constipation
Due to changes in appetite and reduced intake of calories, Mounjaro can cause constipation. Adding more dietary fibre to the diet may help elevate this issue.
5. Abdominal pain
Discomfort in the stomach area is another potential side effect.
These symptoms often subside as the body gets used to it. Serious side effects, although rare, can include pancreatitis, gallbladder issues, kidney problems, allergic reactions and severe gastrointestinal issues.
It is crucial to seek medical attention immediately if you experience severe abdominal pain, changes in urination, or any signs of an allergic reaction.
Safety tips to follow
1. Consult a healthcare professional
Mounjaro is a prescription drug. Always speak to your doctor before starting Mounjaro. They can assess your medical history and determine if it's a suitable option for you.
2. Check blood sugar levels regularly
If you have diabetes, regularly checking your blood sugar levels is essential, especially when starting Mounjaro.
3. Start with low doses
Begin with a low dose to mitigate side effects and allow your body to adjust gradually. However, it is best to administer the dose prescribed by your doctor.
4. Follow a balanced diet
While Mounjaro can aid in weight loss, pairing it with a healthy, balanced diet can help keep digestion healthy.
5. Stay hydrated
Due to potential gastrointestinal effects, ensure you drink plenty of fluids to stay hydrated.
6. Be aware of potential interactions
Check with your doctor if you are currently taking any medication to avoid any potential interactions.
Keep track of any side effects you experience and attend regular check-ups with your doctor. It is advisable to undergo regular kidney function tests, liver function panels, and monitor for any abdominal symptoms while using this medication.
Mounjaro is generally considered safe for use under medical supervision, especially for individuals who are overweight or obese. While it offers substantial benefits, understanding potential side effects and adhering to safety measures is crucial.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
38 minutes ago
- NDTV
Covid More Severe Among Elderly: Kerala Health Minister As Cases Increase
Amid an increase in Covid-19 cases, Kerala Health Minister Veena George has said that special care should be taken as the disease remains more severe among the elderly and those with other diseases. She added that the Omicron JN.1 variants LF.7 and XFG were the most common in Kerala. These variants are "not as severe" but have a high potential for spreading the disease. "Masks should be worn in public places and during travel. Genomic sequencing is being conducted to identify the Covid-19 variant. The Omicron JN.1 variant LF.7 and XFG, which are spreading in Southeast Asian countries, are the most common in Kerala. Although these variants are not as severe, they have a high potential for spreading the disease," the minister said. There are 2,223 active cases in the state, with 96 people undergoing treatment. Ernakulam district reported 431 Covid-19 cases, 426 cases in Kottayam, and 365 in Thiruvananthapuram. "There are currently 2,223 active Covid cases in the state. 96 people are under treatment. Most of them have other diseases. 431 cases have been reported in Ernakulam district, 426 cases in Kottayam and 365 cases in Thiruvananthapuram," the ministry said. All hospitals have been instructed to conduct Covid tests for those with symptoms, including cold, sore throat, cough and shortness of breath. The minister also stated that instructions have been given to ensure oxygen availability. This comes after Ms George chaired a meeting with the state unit of the Rapid Response Team (RRT) to assess the situation in the state. The concerned officials have been directed not to refer patients to private hospitals unnecessarily due to Covid. "Unnecessary visits to hospitals should be avoided. Those with symptoms such as a cold, sore throat, cough and shortness of breath should wear masks. Masks are mandatory in hospitals. Hands should be cleaned with soap or sanitiser from time to time," the minister added. As of Tuesday morning, India has reported 6,815 active Covid-19 cases. According to data from the Indian SARS-CoV-2 Genomics Consortium (INSACOG), 163 cases of the new Covid-19 variant XFG have recently been detected across the country. Earlier, Balram Bhargava, former Director General of the Indian Council of Medical Research (ICMR) and former Secretary of the Department of Health Research, said that the emergence of the XFG variant is part of the SARS-CoV-2 virus's natural evolution. He added that India is well-positioned to detect and contain emerging variants swiftly due to the widespread deployment of rapid molecular diagnostic platforms such as Truenat.
NDTV
12 hours ago
- NDTV
Obesity Injections May Have Fewer Weight Loss Effects In Real World: Study
New Delhi: Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomised clinical trial settings," Dr Gasoyan said. The researchers examined 7,881 adult patients with an average body mass index (BMI) of over 39 -- classified as 'severe obesity'. Of these, 1,320 had pre-diabetes at the start of the study, which meant they were at a higher risk of developing type 2 diabetes. The participants were started on obesity treatments between 2021 and 2023 with semaglutide or tirzepatide injectables. Following up on the participants a year after starting with the treatment, the average weight loss among those who discontinued injections within three months was 3.6 per cent, compared to 6.8 per cent in those who discontinued within 3-12 months. "Mean percentage weight reduction at one year was 8.7 per cent, and it was 3.6 per cent with early discontinuation (three months), 6.8 per cent with late discontinuation (3-12 months) and 11.9 per cent with no discontinuation," the authors wrote. Furthermore, those on a high-maintenance dosage -- the amount required to sustain the effects of the medication -- lost 13.7 per cent of their body weight with semaglutide and 18 per cent with tirzepatide, the researchers said. Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment. "The average weight reduction in this cohort was lower than that observed in the main phase 3 (clinical) trials, likely because of higher rates of discontinuation and lower maintenance dosages," the team wrote. They identified that those not discontinuing medications or taking a high-maintenance dose were among the factors related to more chances of losing at least 10 per cent of one's body weight in a year. Overall, over a fifth of the study group was found to have discontinued their medications within three months of the study's start, while 32 per cent discontinued within 3-12 months. Reasons for discontinuing treatment included costs and insurance-related issues, side effects and medication shortages, the researchers said.
&w=3840&q=100)
Business Standard
13 hours ago
- Business Standard
Obesity injections may have less weight loss effect in reality: Study
Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomised clinical trial settings," Dr Gasoyan said. The researchers examined 7,881 adult patients with an average body mass index (BMI) of over 39 -- classified as 'severe obesity'. Of these, 1,320 had pre-diabetes at the start of the study, which meant they were at a higher risk of developing type 2 diabetes. The participants were started on obesity treatments between 2021 and 2023 with semaglutide or tirzepatide injectables. Following up on the participants a year after starting with the treatment, the average weight loss among those who discontinued injections within three months was 3.6 per cent, compared to 6.8 per cent in those who discontinued within 3-12 months. "Mean percentage weight reduction at one year was 8.7 per cent, and it was 3.6 per cent with early discontinuation (three months), 6.8 per cent with late discontinuation (3-12 months) and 11.9 per cent with no discontinuation," the authors wrote. Furthermore, those on a high-maintenance dosage -- the amount required to sustain the effects of the medication -- lost 13.7 per cent of their body weight with semaglutide and 18 per cent with tirzepatide, the researchers said. Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment. "The average weight reduction in this cohort was lower than that observed in the main phase 3 (clinical) trials, likely because of higher rates of discontinuation and lower maintenance dosages," the team wrote. They identified that those not discontinuing medications or taking a high-maintenance dose were among the factors related to more chances of losing at least 10 per cent of one's body weight in a year. Overall, over a fifth of the study group was found to have discontinued their medications within three months of the study's start, while 32 per cent discontinued within 3-12 months. Reasons for discontinuing treatment included costs and insurance-related issues, side effects and medication shortages, the researchers said.
